ipilimumab,nivolumab,
bms,delcath systems
['chopin']
$dcth positive initial results from chopin phase 1b trial, focus trial update and qol study presented at the 2022 asco annual meeting 
News and analysis of biomedical, biopharma, biotech, biosciences, pharmaceutical, and technology equities